NeOnc Adds UAE Banking Veteran to Board Amid Brain-Cancer Drug Push…

Event summary

NeOnc Technologies Holdings appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank (FAB), to its Board of Directors.
FAB reported AED 1.41 trillion in total assets as of June 30, 2026.
NeOnc secured Department of Health – Abu Dhabi investigational new drug authorizations for both lead candidates, NEO100 and NEO212.
NeOnc reported topline results from its 24-patient NEO100 Phase 2a study, including six-month progression-free survival of 48.9% and median overall survival of 26.09 months.
NeOnc priced a $15 million registered direct offering involving new and existing institutional investors in August 2026.

The big picture

NeOnc’s appointment of Ali Alabedin underscores its strategic push into the UAE, a region positioning itself as a hub for health research and precision medicine. The move comes as NeOnc advances its brain-cancer drug development, seeking to coordinate regulatory requirements, clinical sites, and financing across different healthcare systems. With FAB’s substantial assets and Alabedin’s extensive experience, NeOnc aims to strengthen its financial governance and international business development capabilities, crucial for its multinational clinical-development strategy.

What we're watching

Regulatory Strategy: How NeOnc will leverage Alabedin’s experience to navigate multinational clinical-development complexities and regulatory requirements.
Financial Governance: Whether Alabedin’s international banking and institutional experience will help NeOnc evaluate partnerships and capital requirements for its expansion.
Clinical Execution: The pace at which NeOnc can turn regulatory progress into clinical execution, particularly with its lead candidates NEO100 and NEO212.